


The University of Washington

IDDRC Presents

L16hthouse: Arbaclofen and youth with 16p11.2 Deletion syndrome.

**November 13, 2025 6pm-7pm Eastern
on Zoom**



The “[L16HTHOUSE study](#)” was a Phase 2 clinical trial to examine the safety, tolerability and efficacy of arbaclofen in children with 16p11.2 BP4-BP5 deletion (ClinicalTrials.gov ID: [NCT04271332](#)).

Dr. Paul Wang will present the preliminary results from the trial.

Open to Families, Allies, Clinicians and Scientists.

Please RSVP for [Zoom Link](#)

▼

Post meeting, a recording will be posted :

[IHDD website.](#)

W UNIVERSITY of WASHINGTON



**Center for Autism &
the Developing Brain**